-
公开(公告)号：US20090069297A1
公开(公告)日：2009-03-12
申请号：US12080669
申请日：2008-04-03
申请人： Victor Cee , Holly Deak , Bingfan Du , Stephanie Geuns-Meyer , Brian L. Hodous , Zihao Hua , Mathew Martin , Isaac Marx , Hanh Nho Nguyen , Philip Olivieri , Kathleen Panter , Karina Romero , Laurie Schenkel , Ryan White
发明人： Victor Cee , Holly Deak , Bingfan Du , Stephanie Geuns-Meyer , Brian L. Hodous , Zihao Hua , Mathew Martin , Isaac Marx , Hanh Nho Nguyen , Philip Olivieri , Kathleen Panter , Karina Romero , Laurie Schenkel , Ryan White
IPC分类号： A61K31/502 , C07D237/30 , A61K31/55 , A61P35/00 , C07D403/14
CPC分类号： C07D471/04 , C07D401/12 , C07D401/14 , C07D487/04 , C07D493/04 , C07D495/04
摘要： The present invention relates to chemical compounds having a general formula I wherein A1-8, D′, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.
摘要翻译： 本发明涉及具有通式I的化合物，其中A1-8，D'，L1，L2，R1，R6-8和n定义在本文中，以及合成中间体，其能够调节各种蛋白激酶受体酶和 从而影响与这种激酶的活性相关的各种疾病状态和状况。 例如，化合物能够调节Aurora激酶，从而影响细胞周期和细胞增殖的过程，以治疗癌症和与癌症有关的疾病。 本发明还包括药物组合物，包括该化合物，以及治疗与Aurora激酶活性有关的疾病状态的方法。
-
公开(公告)号：US07776857B2
公开(公告)日：2010-08-17
申请号：US12080669
申请日：2008-04-03
申请人： Victor Cee , Holly Deak , Bingfan Du , Stephanie Geuns-Meyer , Brian L. Hodous , Zihao Hua , Matthew Martin , Isaac Marx , Hanh Nho Nguyen , Philip Olivieri , Kathleen Panter , Karina Romero , Laurie Schenkel , Ryan White
发明人： Victor Cee , Holly Deak , Bingfan Du , Stephanie Geuns-Meyer , Brian L. Hodous , Zihao Hua , Matthew Martin , Isaac Marx , Hanh Nho Nguyen , Philip Olivieri , Kathleen Panter , Karina Romero , Laurie Schenkel , Ryan White
IPC分类号： C07D237/30
CPC分类号： C07D471/04 , C07D401/12 , C07D401/14 , C07D487/04 , C07D493/04 , C07D495/04
摘要： The present invention relates to chemical compounds having a general formula I wherein A1-8, D′, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.
摘要翻译： 本发明涉及具有通式I的化合物，其中A1-8，D'，L1，L2，R1，R6-8和n定义在本文中，以及合成中间体，其能够调节各种蛋白激酶受体酶和 从而影响与这种激酶的活性相关的各种疾病状态和状况。 例如，化合物能够调节Aurora激酶，从而影响细胞周期和细胞增殖的过程，以治疗癌症和与癌症有关的疾病。 本发明还包括药物组合物，包括该化合物，以及治疗与Aurora激酶活性有关的疾病状态的方法。
-
公开(公告)号：US20120122847A1
公开(公告)日：2012-05-17
申请号：US13157195
申请日：2011-06-09
申请人： Victor Cee , Holly Deak , Bingfan Du , Stephanie Geuns-Meyer , Zihao Hua , Matthew Martin , Issac Marx , Hanh Nho Nguyen , Philip Olivieri , Kathleen Panter , Karina Romero , Laurie Schenkel , Ryan White
发明人： Victor Cee , Holly Deak , Bingfan Du , Stephanie Geuns-Meyer , Zihao Hua , Matthew Martin , Issac Marx , Hanh Nho Nguyen , Philip Olivieri , Kathleen Panter , Karina Romero , Laurie Schenkel , Ryan White
IPC分类号： A61K31/502 , A61P35/00 , C07D413/14 , A61K31/5377 , C07D471/04 , A61K31/55
CPC分类号： C07D471/04 , C07D401/12 , C07D401/14 , C07D487/04 , C07D493/04 , C07D495/04
摘要： The present invention relates to chemical compounds having a general formula I wherein A1-8, D′, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.
摘要翻译： 本发明涉及具有通式I的化合物，其中A1-8，D'，L1，L2，R1，R6-8和n定义在本文中，以及合成中间体，其能够调节各种蛋白激酶受体酶和 从而影响与这种激酶的活性相关的各种疾病状态和状况。 例如，化合物能够调节Aurora激酶，从而影响细胞周期和细胞增殖的过程，以治疗癌症和与癌症有关的疾病。 本发明还包括药物组合物，包括该化合物，以及治疗与Aurora激酶活性有关的疾病状态的方法。
-
公开(公告)号：US20100280008A1
公开(公告)日：2010-11-04
申请号：US12828067
申请日：2010-06-30
申请人： Holly Deak , Stephanie Geuns-Meyer , Brian L. Hodous , Zihao Hua , Matthew Martin , Hanh Nho Nguyen , Philip Olivieri , Kathleen Panter , Karina Romero , Laurie Schenkel , Ryan White
发明人： Holly Deak , Stephanie Geuns-Meyer , Brian L. Hodous , Zihao Hua , Matthew Martin , Hanh Nho Nguyen , Philip Olivieri , Kathleen Panter , Karina Romero , Laurie Schenkel , Ryan White
IPC分类号： A61K31/55 , A61K31/5377 , A61K31/502 , C07D413/14 , C07D401/14 , C07D401/12 , A61P35/00
CPC分类号： C07D471/04 , C07D401/12 , C07D401/14 , C07D487/04 , C07D493/04 , C07D495/04
摘要： The present invention relates to chemical compounds having a general formula I wherein A1-8, D′, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.
摘要翻译： 本发明涉及具有通式I的化合物，其中A1-8，D'，L1，L2，R1，R6-8和n定义在本文中，以及合成中间体，其能够调节各种蛋白激酶受体酶和 从而影响与这种激酶的活性相关的各种疾病状态和状况。 例如，化合物能够调节Aurora激酶，从而影响细胞周期和细胞增殖的过程，以治疗癌症和与癌症有关的疾病。 本发明还包括药物组合物，包括该化合物，以及治疗与Aurora激酶活性有关的疾病状态的方法。
-
公开(公告)号：US07981891B2
公开(公告)日：2011-07-19
申请号：US12828067
申请日：2010-06-30
申请人： Holly Deak , Stephanie Geuns-Meyer , Brian L. Hodous , Zihao Hua , Mathew Martin , Hanh Nho Nguyen , Philip Olivieri , Kate Panter , Karina Romero , Laurie Schenkel , Ryan White
发明人： Holly Deak , Stephanie Geuns-Meyer , Brian L. Hodous , Zihao Hua , Mathew Martin , Hanh Nho Nguyen , Philip Olivieri , Kate Panter , Karina Romero , Laurie Schenkel , Ryan White
IPC分类号： A61K31/502
CPC分类号： C07D471/04 , C07D401/12 , C07D401/14 , C07D487/04 , C07D493/04 , C07D495/04
摘要： The present invention relates to chemical compounds having a general formula I wherein A1-8, D′, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.
摘要翻译： 本发明涉及具有通式I的化合物，其中A1-8，D'，L1，L2，R1，R6-8和n定义在本文中，以及合成中间体，其能够调节各种蛋白激酶受体酶和 从而影响与这种激酶的活性相关的各种疾病状态和状况。 例如，化合物能够调节Aurora激酶，从而影响细胞周期和细胞增殖的过程，以治疗癌症和与癌症有关的疾病。 本发明还包括药物组合物，包括该化合物，以及治疗与Aurora激酶活性有关的疾病状态的方法。
-
公开(公告)号：US20070185111A1
公开(公告)日：2007-08-09
申请号：US11655642
申请日：2007-01-18
申请人： Victor Cee , Holly Deak , Bingfan Du , Stephanie Geuns-Meyer , Brian Hodous , Hanh Nguyen , Philip Olivieri , Vinod Patel , Karina Romero , Laurie Schenkel
发明人： Victor Cee , Holly Deak , Bingfan Du , Stephanie Geuns-Meyer , Brian Hodous , Hanh Nguyen , Philip Olivieri , Vinod Patel , Karina Romero , Laurie Schenkel
IPC分类号： A61K31/53 , A61K31/503 , C07D403/14
CPC分类号： C07D401/14 , C07D237/30 , C07D239/42 , C07D401/04 , C07D409/04 , C07D409/14 , C07D417/14 , C07D471/04 , C07D491/048 , C07D495/04 , C07D497/04
摘要： The present invention relates to chemical compounds having a general formula I wherein A1, A2, C1, C2, D, L1, L2, Z and R1- are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.
摘要翻译： 本发明涉及具有通式I的化合物，其中A 1，A 2，C 1，C 2， 本文定义的SUP，D，L 1，L 2，Z和R 1 - 以及能够调节的合成中间体 各种蛋白激酶受体酶，从而影响与这些激酶的活性相关的各种疾病状态和病症。 例如，化合物能够调节Aurora激酶，从而影响细胞周期和细胞增殖的过程，以治疗癌症和与癌症有关的疾病。 本发明还包括药物组合物，包括该化合物，以及治疗与Aurora激酶活性有关的疾病状态的方法。
-
公开(公告)号：US20070213325A1
公开(公告)日：2007-09-13
申请号：US11709994
申请日：2007-02-21
申请人： Victor Cee , Holly Deak , Stephanie Geuns-Meyer , Brian Hodous , Hanh Nho Nguyen , Philip Olivieri , Vinod Patel , Karina Romero
发明人： Victor Cee , Holly Deak , Stephanie Geuns-Meyer , Brian Hodous , Hanh Nho Nguyen , Philip Olivieri , Vinod Patel , Karina Romero
IPC分类号： A61K31/541 , A61K31/5377 , A61K31/506 , A61K31/53 , C07D403/02 , C07D413/02 , C07D417/02
CPC分类号： C07D403/12 , C07D401/14 , C07D413/14 , C07D417/14
摘要： The present invention relates to chemical compounds having a general formula I wherein A, B, C1, C2, D, L1, L2 and R3-4 are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Tie-2 and Aurora kinase enzymes thereby influencing angiogenesis and the process of cell cycle and cell proliferation, respectively, to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of various protein kinases.
摘要翻译： 本发明涉及具有通式I的化合物，其中A，B，C 1，C 2，D，L 1，L 本文定义了本发明的第二和第三和第三十四种以及合成中间体，其能够调节各种蛋白激酶受体酶，从而影响各种疾病状态和与 这种激酶的活性。 例如，化合物能够调节Tie-2和Aurora激酶，从而分别影响血管发生和细胞周期和细胞增殖过程，以治疗癌症和癌症相关疾病。 本发明还包括药物组合物，包括该化合物，以及治疗与各种蛋白激酶活性有关的疾病状态的方法。
-
公开(公告)号：US20060009453A1
公开(公告)日：2006-01-12
申请号：US11126000
申请日：2005-05-09
申请人： Stephanie Geuns-Meyer , Brian Hodous , Stuart Chaffee , Paul Tempest , Philip Olivieri , Rebecca Johnson , Brian Albrecht , Vinod Patel , Victor Cee , Joseph Kim , Steven Bellon , Xiaotian Zhu , Yuan Cheng , Ning Xi , Karina Romero , Hanh Nguyen , Holly Deak
发明人： Stephanie Geuns-Meyer , Brian Hodous , Stuart Chaffee , Paul Tempest , Philip Olivieri , Rebecca Johnson , Brian Albrecht , Vinod Patel , Victor Cee , Joseph Kim , Steven Bellon , Xiaotian Zhu , Yuan Cheng , Ning Xi , Karina Romero , Hanh Nguyen , Holly Deak
IPC分类号： A61K31/53 , A61K31/506 , C07D43/14
CPC分类号： C07D213/73 , C07D239/42 , C07D401/04 , C07D401/14 , C07D405/14 , C07D407/14 , C07D409/14 , C07D413/14 , C07D471/04
摘要： The present invention relates to chemical compounds having a general formula I wherein A, B, D, E, G, H1-5 and R1-4 are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of these kinases. For example, the compounds are capable of modulating kinase enzymes thereby influencing the process of angiogenesis and treating angiogenesis-related diseases and other poliferative disorders, including cancer and inflammation. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of protein kinases.
摘要翻译： 本发明涉及具有通式I的化合物，其中A，B，D，E，G，H 1-5和R 1-4如本文所定义， 和合成中间体，其能够调节各种蛋白激酶受体酶，从而影响与这些激酶的活性相关的各种疾病状态和状况。 例如，这些化合物能够调节激酶，从而影响血管生成过程并治疗血管生成相关疾病和其它包括癌症和炎症的复发性疾病。 本发明还包括药物组合物，包括该化合物，以及治疗与蛋白激酶活性有关的疾病状态的方法。
-
公开(公告)号：US20070054916A1
公开(公告)日：2007-03-08
申请号：US11240590
申请日：2005-09-30
申请人： Vinod Patel , Joseph Kim , Stephanie Geuns-Meyer , Stuart Chaffee , Victor Cee , Brian Hodous , Steven Bellon , Jean-Christophe Harmange , Philip Olivieri , Maya Thaman , Erin DiMauro , John Buchanan , David McGowan , Brian Albrecht , Holly Deak , Jean Bemis , Ryan White , Matthew Martin , Gregory Habgood , Paul Tempest , Craig Masse , William Buckner , Bradley Herberich , Russell Graceffa , Dawei Zhang , Shimin Xu , Kelvin Sham , Robert Rzasa , James Falsey , Partha Chakrabarti , Guo-Qiang Cao , Susan Tomlinson , Liping Pettus , Adrian Smith , Nick Paras , Gang Liu , Frenel DeMorin , Andrew Tasker , Anthony Reed
发明人： Vinod Patel , Joseph Kim , Stephanie Geuns-Meyer , Stuart Chaffee , Victor Cee , Brian Hodous , Steven Bellon , Jean-Christophe Harmange , Philip Olivieri , Maya Thaman , Erin DiMauro , John Buchanan , David McGowan , Brian Albrecht , Holly Deak , Jean Bemis , Ryan White , Matthew Martin , Gregory Habgood , Paul Tempest , Craig Masse , William Buckner , Bradley Herberich , Russell Graceffa , Dawei Zhang , Shimin Xu , Kelvin Sham , Robert Rzasa , James Falsey , Partha Chakrabarti , Guo-Qiang Cao , Susan Tomlinson , Liping Pettus , Adrian Smith , Nick Paras , Gang Liu , Frenel DeMorin , Andrew Tasker , Anthony Reed
IPC分类号： A61K31/525 , A61K31/519 , A61K31/517
CPC分类号： C07D215/38 , C07C205/37 , C07D215/12 , C07D217/12 , C07D217/22 , C07D217/26 , C07D239/26 , C07D239/84 , C07D239/94 , C07D239/95 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/12 , C07D409/04 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/12 , C07D471/04 , C07D487/04 , C07D495/04
摘要： The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation, cancer and related conditions. The compounds have a general Formula I wherein A1, A2, A3, B, R1, R2, R3 and R4 are defined herein. Accordingly, the invention also comprises pharmaceutical compositions comprising the compounds of the invention, methods for the prophylaxis and treatment of kinase mediated diseases using the compounds and compositions of the invention, and intermediates and processes useful for the preparation of compounds of the invention.
摘要翻译： 本发明包括一类新的可用于预防和治疗蛋白激酶介导的疾病，包括炎症，癌症和相关病症的化合物。 化合物具有通式I，其中A 1，A 2，A 3，B，R 1， R 2，R 3和R 4在本文中定义。 因此，本发明还包括含有本发明化合物的药物组合物，使用本发明化合物和组合物预防和治疗激酶介导的疾病的方法，以及可用于制备本发明化合物的中间体和方法。
-
公开(公告)号：US08557816B2
公开(公告)日：2013-10-15
申请号：US13157195
申请日：2011-06-09
IPC分类号： A61K31/502
CPC分类号： C07D471/04 , C07D401/12 , C07D401/14 , C07D487/04 , C07D493/04 , C07D495/04
摘要： The present invention relates to chemical compounds having a general formula I wherein A1-8, D′, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.
-
-
-
-
-
-
-
-
-
搜索结果
17 条记录 (耗时 0.09 秒)
